A 66-year-old woman developed injection site reaction following treatment with anakinra [dosage not stated; route not stated clearly]. The woman, who had adult-onset Still's disease, started receiving treatment with anakinra injections. Her concurrent medication included methylprednisolone. Subsequently, the woman developed injection site reaction secondary to anakinra. Therefore, the anakinra therapy was discontinued. Subsequently, she was switched to canakinumab. However, later, she was treated with hydroxychloroquine with a short initial boost of anakinra [duration of treatment to reaction onset and outcome not stated].

Author comment: "However, due to injection site reactions caused by anakinra and after obtaining her consent and authorities approval, she was switched to canakinumab 150 mg/8 weeks."